Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Characterization of Tetracycline Hydrochloride Compounded in a Miracle Mouthwash Formulation.

Younis US, Fazel M, Myrdal PB.

AAPS PharmSciTech. 2019 Apr 30;20(5):178. doi: 10.1208/s12249-019-1388-x.

PMID:
31041553
2.

Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma.

Younis US, Vallorz E, Addison KJ, Ledford JG, Myrdal PB.

AAPS PharmSciTech. 2019 Apr 16;20(5):167. doi: 10.1208/s12249-019-1377-0.

PMID:
30993508
3.

Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice.

Blohm-Mangone K, Burkett NB, Tahsin S, Myrdal PB, Aodah A, Ho B, Janda J, McComas M, Saboda K, Roe DJ, Dong Z, Bode AM, Petricoin EF 3rd, Calvert VS, Curiel-Lewandrowski C, Alberts DS, Wondrak GT, Dickinson SE.

Cancer Prev Res (Phila). 2018 May;11(5):265-278. doi: 10.1158/1940-6207.CAPR-17-0349. Epub 2018 Feb 1.

4.

Impact of droplet evaporation rate on resulting in vitro performance parameters of pressurized metered dose inhalers.

Sheth P, Grimes MR, Stein SW, Myrdal PB.

Int J Pharm. 2017 Aug 7;528(1-2):360-371. doi: 10.1016/j.ijpharm.2017.06.014. Epub 2017 Jun 6.

PMID:
28599855
5.

The effect of a holding chamber on albuterol metered-dose inhaler product differences.

Johnson JL, Guthrie D, Hyde J, Hanson T, Karlage K, Myrdal PB.

Ann Allergy Asthma Immunol. 2016 Sep;117(3):246-50. doi: 10.1016/j.anai.2016.07.016.

PMID:
27613457
6.

Estimating the Aqueous Solubility of Pharmaceutical Hydrates.

Franklin SJ, Younis US, Myrdal PB.

J Pharm Sci. 2016 Jun;105(6):1914-1919. doi: 10.1016/j.xphs.2016.03.040.

7.

Preformulation Studies on Piperlongumine.

Aodah A, Pavlik A, Karlage K, Myrdal PB.

PLoS One. 2016 Mar 16;11(3):e0151707. doi: 10.1371/journal.pone.0151707. eCollection 2016.

8.

Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.

Jeter JM, Curiel-Lewandrowski C, Stratton SP, Myrdal PB, Warneke JA, Einspahr JG, Bartels HG, Yozwiak M, Bermudez Y, Hu C, Bartels P, Alberts DS.

Cancer Prev Res (Phila). 2016 Feb;9(2):128-34. doi: 10.1158/1940-6207.CAPR-15-0232. Epub 2015 Dec 28.

9.

Modeling and Understanding Combination pMDI Formulations with Both Dissolved and Suspended Drugs.

Stein SW, Sheth P, Younis US, Mogalian E, Myrdal PB.

Mol Pharm. 2015 Sep 8;12(9):3455-67. doi: 10.1021/acs.molpharmaceut.5b00467. Epub 2015 Aug 24.

PMID:
26258647
10.

Solid-State and Solution Characterization of Myricetin.

Franklin SJ, Myrdal PB.

AAPS PharmSciTech. 2015 Dec;16(6):1400-8. doi: 10.1208/s12249-015-0329-6. Epub 2015 May 19.

11.

Factors influencing aerodynamic particle size distribution of suspension pressurized metered dose inhalers.

Sheth P, Stein SW, Myrdal PB.

AAPS PharmSciTech. 2015 Feb;16(1):192-201. doi: 10.1208/s12249-014-0210-z. Epub 2014 Oct 2.

12.

In vitro evaluation of nonconventional accessory devices for pressurized metered-dose inhalers.

Sheth P, Bertsch MD, Knapp CL, Myrdal PB.

Ann Allergy Asthma Immunol. 2014 Jul;113(1):55-62. doi: 10.1016/j.anai.2014.04.006. Epub 2014 May 9.

PMID:
24814758
13.

Advances in metered dose inhaler technology: formulation development.

Myrdal PB, Sheth P, Stein SW.

AAPS PharmSciTech. 2014 Apr;15(2):434-55. doi: 10.1208/s12249-013-0063-x. Epub 2014 Jan 23. Review.

14.

Advances in metered dose inhaler technology: hardware development.

Stein SW, Sheth P, Hodson PD, Myrdal PB.

AAPS PharmSciTech. 2014 Apr;15(2):326-38. doi: 10.1208/s12249-013-0062-y. Epub 2013 Dec 20. Review.

15.

The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers.

Sheth P, Stein SW, Myrdal PB.

Int J Pharm. 2013 Oct 15;455(1-2):57-65. doi: 10.1016/j.ijpharm.2013.07.061. Epub 2013 Aug 1.

PMID:
23911912
16.

Stability of sulforaphane for topical formulation.

Franklin SJ, Dickinson SE, Karlage KL, Bowden GT, Myrdal PB.

Drug Dev Ind Pharm. 2014 Apr;40(4):494-502. doi: 10.3109/03639045.2013.768634. Epub 2013 Apr 23.

17.

Comparative evaluation of pharmaceutical products obtained in Mexico: augmenting existing scientific data.

Karlage KL, Franklin SJ, Mufich WC, Goetz KJ, Sabelka JV, Hoye WL, Myrdal PB.

Drug Dev Ind Pharm. 2012 Jul;38(7):808-14. doi: 10.3109/03639045.2011.628678. Epub 2011 Nov 17.

PMID:
22091930
18.

A model for predicting size distributions delivered from pMDIs with suspended drug.

Stein SW, Sheth P, Myrdal PB.

Int J Pharm. 2012 Jan 17;422(1-2):101-15. doi: 10.1016/j.ijpharm.2011.10.035. Epub 2011 Oct 21.

PMID:
22044537
19.

Stability of midazolam hydrochloride injection 1-mg/mL solutions in polyvinyl chloride and polyolefin bags.

Karlage K, Earhart Z, Green-Boesen K, Myrdal PB.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1537-40. doi: 10.2146/ajhp100413.

PMID:
21817086
20.

Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination.

Guo D, Myrdal PB, Karlage KL, O'Connell SP, Wissinger TJ, Tabibi SE, Yalkowsky SH.

AAPS PharmSciTech. 2010 Mar;11(1):247-52. doi: 10.1208/s12249-010-9383-2. Epub 2010 Feb 12.

21.

A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer.

Stratton SP, Alberts DS, Einspahr JG, Sagerman PM, Warneke JA, Curiel-Lewandrowski C, Myrdal PB, Karlage KL, Nickoloff BJ, Brooks C, Saboda K, Yozwiak ML, Krutzsch MF, Hu C, Lluria-Prevatt M, Dong Z, Bowden GT, Bartels PH.

Cancer Prev Res (Phila). 2010 Feb;3(2):160-9. doi: 10.1158/1940-6207.CAPR-09-0183. Epub 2010 Jan 26.

22.

Inhalation of an ethanol-based zileuton formulation provides a reduction of pulmonary adenomas in the A/J mouse model.

Karlage KL, Mogalian E, Jensen A, Myrdal PB.

AAPS PharmSciTech. 2010 Mar;11(1):168-73. doi: 10.1208/s12249-009-9371-6. Epub 2010 Jan 26.

23.

Preformulation, formulation, and in vivo efficacy of topically applied apomine.

Kuehl PJ, Stratton SP, Powell MB, Myrdal PB.

Int J Pharm. 2009 Dec 1;382(1-2):104-10. doi: 10.1016/j.ijpharm.2009.08.016. Epub 2009 Aug 20.

24.

Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications.

Hill SW, Varker AS, Karlage K, Myrdal PB.

J Manag Care Pharm. 2009 Apr;15(3):253-61.

25.

Accounting for the effects of moderately increased pressure on the energetics of melting and solubility in metered dose inhalers.

Mogalian E, Sepassi K, Myrdal PB.

Drug Dev Ind Pharm. 2008 Sep;34(9):930-5. doi: 10.1080/03639040802154871 .

PMID:
18800253
26.

Measurement and correlation of solute solubility in HFA-134a/ethanol systems.

Hoye JA, Myrdal PB.

Int J Pharm. 2008 Oct 1;362(1-2):184-8. doi: 10.1016/j.ijpharm.2008.06.020. Epub 2008 Jul 4.

PMID:
18647644
27.

Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer.

Stratton SP, Saboda KL, Myrdal PB, Gupta A, McKenzie NE, Brooks C, Salasche SJ, Warneke JA, Ranger-Moore J, Bozzo PD, Blanchard J, Einspahr JG, Dorr RT, Levine N, Alberts DS.

Nutr Cancer. 2008;60(3):325-30. doi: 10.1080/01635580701840391.

PMID:
18444166
28.

Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor.

Sanghvi R, Mogalian E, Machatha SG, Narazaki R, Karlage KL, Jain P, Tabibi SE, Glaze E, Myrdal PB, Yalkowsky SH.

J Pharm Sci. 2009 Jan;98(1):205-14. doi: 10.1002/jps.21421.

PMID:
18428980
29.

Formulation and in vivo evaluation of chlorpropham (CIPC) oral formulations.

Kuehl PJ, Brenner T, Jain PK, Karlage K, Sepassi K, Yang G, Mayersohn M, Yalkowsky SH, Myrdal PB.

J Pharm Sci. 2008 Dec;97(12):5222-8. doi: 10.1002/jps.21384.

PMID:
18383335
30.

Solubility of solid solutes in HFA-134a with a correlation to physico-chemical properties.

Hoye JA, Gupta A, Myrdal PB.

J Pharm Sci. 2008 Jan;97(1):198-208.

PMID:
17828733
31.

New analytical techniques to facilitate preformulation screening in propellant systems.

Mogalian E, Kuehl PJ, Myrdal PB.

Int J Pharm. 2007 Aug 1;340(1-2):223-9. Epub 2007 Mar 25.

PMID:
17498897
32.

Application of heated inlet extensions to the TSI 3306/3321 system: comparison with the Andersen cascade impactor and next generation impactor.

Myrdal PB, Mogalian E, Mitchell J, Nagel M, Wright C, Kiser B, Prell M, Woessner M, Stein SW.

J Aerosol Med. 2006 Winter;19(4):543-54.

PMID:
17196082
33.

Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation.

Myrdal PB, Karlage K, Kuehl PJ, Angersbach BS, Merrill BA, Wightman PD.

Carcinogenesis. 2007 May;28(5):957-61. Epub 2006 Nov 17.

PMID:
17114645
34.

Chiral separation of lipoxygenase metabolites utilizing high-performance liquid chromatography.

Myrdal PB, Angersbach BS, Karlage K, Kuehl PJ.

J Chromatogr A. 2006 Nov 3;1132(1-2):315-9. Epub 2006 Sep 26.

PMID:
17005188
35.

Preformulation studies on imexon.

Kuehl PJ, Hoye WL, Myrdal PB.

Drug Dev Ind Pharm. 2006 Jul;32(6):687-97.

PMID:
16885124
36.

Evaluation of the TSI aerosol impactor 3306/3321 system using a redesigned impactor stage with solution and suspension metered-dose inhalers.

Harris JA, Stein SW, Myrdal PB.

AAPS PharmSciTech. 2006 Mar 10;7(1):E20. Erratum in: AAPS PharmSciTech. 2006;7(3):E1.

37.

Evaluation of the TSI aerosol impactor 3306/3321 system using a redesigned impactor stage with solution and suspension metered-dose inhalers.

Harris JA, Stein SW, Myrdal PB.

AAPS PharmSciTech. 2006 Mar;7(1):E138-E145. doi: 10.1208/pt070120. Epub 2017 Mar 8.

PMID:
28290035
38.

Comparison of three pharmaceutical products obtained from Mexico and the United States: a case study.

Karlage KL, Myrdal PB.

Drug Dev Ind Pharm. 2005 Dec;31(10):993-1000.

PMID:
16316855
39.
40.

Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols.

Hoye WL, Mogalian EM, Myrdal PB.

Am J Health Syst Pharm. 2005 Nov 1;62(21):2271-7.

PMID:
16239418
41.

Development of an HPLC method for the analysis of Apomine in a topical cream formulation.

Kuehl PJ, Angersbach BS, Stratton SP, Myrdal PB.

J Pharm Biomed Anal. 2006 Mar 3;40(4):975-80. Epub 2005 Sep 21.

PMID:
16181759
42.

An HPLC method for quantitation of perillyl alcohol in a topical pharmaceutical cream formulation.

Gupta A, Stratton SP, Myrdal PB.

J Pharm Biomed Anal. 2005 Mar 9;37(3):447-52. Epub 2005 Jan 13.

PMID:
15740902
43.

A comparison of two methods to determine the solubility of compounds in aerosol propellants.

Gupta A, Myrdal PB.

Int J Pharm. 2005 Mar 23;292(1-2):201-9.

PMID:
15725567
44.

Comparison of the TSI Model 3306 Impactor Inlet with the Andersen Cascade Impactor: solution metered dose inhalers.

Myrdal PB, Stein SW, Mogalian E, Hoye W, Gupta A.

Drug Dev Ind Pharm. 2004 Sep;30(8):859-68.

PMID:
15521331
45.

Novel method for the determination of solubility in aerosol propellants.

Gupta A, Myrdal PB.

J Pharm Sci. 2004 Oct;93(10):2411-9.

PMID:
15349951
46.
47.
48.

Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane-based metered dose inhalers.

Myrdal PB, Karlage KL, Stein SW, Brown BA, Haynes A.

J Pharm Sci. 2004 Apr;93(4):1054-61.

PMID:
14999741
49.

Development of a perillyl alcohol topical cream formulation.

Gupta A, Myrdal PB.

Int J Pharm. 2004 Jan 28;269(2):373-83.

PMID:
14706249
50.

Supplemental Content

Loading ...
Support Center